Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Telomere length in relation to immunological parameters in patients with renal cell carcinoma.

Svenson U, Grönlund E, Söderström I, Sitaram RT, Ljungberg B, Roos G.

PLoS One. 2013;8(2):e55543. doi: 10.1371/journal.pone.0055543. Epub 2013 Feb 1.

2.

Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer.

Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X.

J Urol. 2007 Oct;178(4 Pt 1):1492-6. Epub 2007 Aug 16.

PMID:
17707063
3.

Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells.

Busse A, Asemissen A, Nonnenmacher A, Ochsenreither S, Fusi A, Braun F, Stather D, Schmittel A, Miller K, Thiel E, Keilholz U.

J Immunother. 2011 Jan;34(1):113-9. doi: 10.1097/CJI.0b013e3181fb6580.

PMID:
21150720
4.

Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma.

Svenson U, Ljungberg B, Roos G.

Cancer Res. 2009 Apr 1;69(7):2896-901. doi: 10.1158/0008-5472.CAN-08-3513. Epub 2009 Mar 24.

6.

Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity.

Spyridopoulos I, Hoffmann J, Aicher A, Brümmendorf TH, Doerr HW, Zeiher AM, Dimmeler S.

Circulation. 2009 Oct 6;120(14):1364-72. doi: 10.1161/CIRCULATIONAHA.109.854299. Epub 2009 Sep 21.

7.

Telomere dysfunction: a potential cancer predisposition factor.

Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR.

J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8.

8.

Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine.

Wolf B, Schwarzer A, Côté AL, Hampton TH, Schwaab T, Huarte E, Tomlinson CR, Gui J, Fisher JL, Fadul CE, Hamilton JW, Ernstoff MS.

PLoS One. 2012;7(12):e50221. doi: 10.1371/journal.pone.0050221. Epub 2012 Dec 3.

9.

Risk of renal cell carcinoma in relation to blood telomere length in a population-based case-control study.

Hofmann JN, Baccarelli A, Schwartz K, Davis FG, Ruterbusch JJ, Hoxha M, McCarthy BJ, Savage SA, Wacholder S, Rothman N, Graubard BI, Colt JS, Chow WH, Purdue MP.

Br J Cancer. 2011 Nov 22;105(11):1772-5. doi: 10.1038/bjc.2011.444. Epub 2011 Oct 27.

10.

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL.

J Clin Oncol. 2006 Mar 1;24(7):1169-77.

11.

Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.

Rayman P, Uzzo RG, Kolenko V, Bloom T, Cathcart MK, Molto L, Novick AC, Bukowski RM, Hamilton T, Finke JH.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S81-7.

PMID:
10685665
12.

Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.

Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, Peereboom D, Olencki T, Budd GT, McLain D, Elson P, Novick A, Finke JH.

Clin Cancer Res. 1998 Oct;4(10):2337-47.

13.

[Polymorphisms in inflammatory response genes in metastatic renal cancer].

Sáenz López P, Vázquez Alonso F, Romero JM, Carretero R, Tallada Buñuel M, Ruiz Cabello F, Cózar Olmo JM.

Actas Urol Esp. 2009 May;33(5):474-81. Spanish.

PMID:
19658300
14.

Frequency and gene expression profile of regulatory T cells in renal cell carcinoma.

Jeron A, Pfoertner S, Bruder D, Geffers R, Hammerer P, Hofmann R, Buer J, Schrader AJ.

Tumour Biol. 2009;30(3):160-70. doi: 10.1159/000228909. Epub 2009 Jul 16.

PMID:
19609102
15.

Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia.

Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K, Ido A, Matsuoka H, Okayama A, Nakanishi T, Tsubouchi H.

Leuk Lymphoma. 2005 Mar;46(3):393-9.

PMID:
15621829
16.

Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes.

Shabtai M, Ye H, Frischer Z, Martin J, Waltzer WC, Malinowski K.

J Urol. 2002 Nov;168(5):2216-9.

PMID:
12394762
17.

Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.

Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT.

Cancer Immunol Immunother. 1995 Aug;41(2):111-21.

PMID:
7656270
18.

Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.

Böhm M, Ittenson A, Klatte T, Schierbaum KF, Röhl FW, Ansorge S, Allhoff EP.

Folia Biol (Praha). 2003;49(2):63-8.

PMID:
12779014
19.

Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.

Donskov F, Bennedsgaard KM, Von Der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P, Hokland M.

Br J Cancer. 2002 Jul 15;87(2):194-201.

20.

Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma.

Jensen HK, Donskov F, Nordsmark M, Marcussen N, von der Maase H.

Clin Cancer Res. 2009 Feb 1;15(3):1052-8. doi: 10.1158/1078-0432.CCR-08-1296.

Items per page

Supplemental Content

Write to the Help Desk